Phase II evaluation of bleomycin. A Southwest oncology Group study.
作者： Charles D. Haas , Charles A. Coltman , Jeffrey A. Gottlieb , Arthur Haut , James K. Luce
DOI: 10.1002/1097-0142(197607)38:1<8::AID-CNCR2820380103>3.0.CO;2-4
关键词: Squamous cell cancer 、 Lung toxicity 、 Internal medicine 、 Pulmonary toxicity 、 Renal adenocarcinoma 、 Toxicity 、 Group study 、 Medicine 、 Oncology 、 Bleomycin
摘要: Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice-weekly doses of 10 mg/m2 was evaluated for efficacy and toxicity 382 patients. Responses were observed 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers ectodermal origin, 12/26 germinal cancers, 3/8 renal adenocarcinomas. The i.m. route is less likely to casue pulmonary hypotension than the i.v. route. Advanced age total exceeding 200 mg associated with a higher risk lung toxicity. All responders had shown at least improvement upon receiving mg; should be used only responding
sci-hub.se 参考文章(8)
Richard A. Rudders, Treatment of advanced malignant lymphomas with bleomycin. Blood. ,vol. 40, pp. 317- 332 ,(1972) , 10.1182/BLOOD.V40.3.317.317
R. M. Humphrey, S. C. Barranco, The Effects of Bleomycin on Survival and Cell Progression in Chinese Hamster Cells in Vitro Cancer Research. ,vol. 31, pp. 1218- 1223 ,(1971)
Walter N. Hittelman, Potu N. Rao, Bleomycin-induced Damage in Prematurely Condensed Chromosomes and Its Relationship to Cell Cycle Progression in CHO Cells Cancer Research. ,vol. 34, pp. 3433- 3439 ,(1974)
Robert W. Talley, Chemotherapy of adenocarcinoma of the kidney Cancer. ,vol. 32, pp. 1062- 1065 ,(1973) , 10.1002/1097-0142(197311)32:5<1062::AID-CNCR2820320506>3.0.CO;2-U
Barth Hoogstraten, Charles D. Haas, Arthur Haut, Robert W. Talley, Saul Rivkin, Bertha L. Isaacs, CCNU and bleomycin in the treatment of cancer: a Southwest Oncology Group Study. Medical and Pediatric Oncology. ,vol. 1, pp. 95- 106 ,(1975) , 10.1002/MPO.2950010204
Ronald H. Blum, Stephen K. Carter, Karl Agre, A clinical review of bleomycin—a new antineoplastic agent Cancer. ,vol. 31, pp. 903- 914 ,(1973) , 10.1002/1097-0142(197304)31:4<903::AID-CNCR2820310422>3.0.CO;2-N
Chalbaud Ra, Johnson De, Holoye Py, Samuels Ml, Clinical trial of bleomycin (NSC-125066) in the treatment of metastatic renal carcinoma. Cancer chemotherapy reports. ,vol. 59, pp. 433- ,(1975)
Coltman Ca, Spigel Sc, Vinblastine (NSC-49842) and bleomycin (NSC-125066) therapy for disseminated testicular tumors. Cancer chemotherapy reports. ,vol. 58, pp. 213- ,(1974)